全文获取类型
收费全文 | 125072篇 |
免费 | 8237篇 |
国内免费 | 542篇 |
专业分类
耳鼻咽喉 | 1320篇 |
儿科学 | 3685篇 |
妇产科学 | 2077篇 |
基础医学 | 16660篇 |
口腔科学 | 2222篇 |
临床医学 | 12308篇 |
内科学 | 26526篇 |
皮肤病学 | 1518篇 |
神经病学 | 12087篇 |
特种医学 | 3846篇 |
外国民族医学 | 1篇 |
外科学 | 18040篇 |
综合类 | 1681篇 |
现状与发展 | 1篇 |
一般理论 | 156篇 |
预防医学 | 10919篇 |
眼科学 | 3347篇 |
药学 | 8826篇 |
1篇 | |
中国医学 | 279篇 |
肿瘤学 | 8351篇 |
出版年
2023年 | 615篇 |
2022年 | 1080篇 |
2021年 | 2410篇 |
2020年 | 1428篇 |
2019年 | 2446篇 |
2018年 | 2850篇 |
2017年 | 2069篇 |
2016年 | 2406篇 |
2015年 | 2782篇 |
2014年 | 4012篇 |
2013年 | 5633篇 |
2012年 | 8594篇 |
2011年 | 9234篇 |
2010年 | 5064篇 |
2009年 | 4703篇 |
2008年 | 8147篇 |
2007年 | 8642篇 |
2006年 | 8205篇 |
2005年 | 8224篇 |
2004年 | 7774篇 |
2003年 | 7161篇 |
2002年 | 6912篇 |
2001年 | 1216篇 |
2000年 | 906篇 |
1999年 | 1244篇 |
1998年 | 1499篇 |
1997年 | 1251篇 |
1996年 | 974篇 |
1995年 | 963篇 |
1994年 | 807篇 |
1993年 | 800篇 |
1992年 | 672篇 |
1991年 | 621篇 |
1990年 | 548篇 |
1989年 | 507篇 |
1988年 | 509篇 |
1987年 | 489篇 |
1986年 | 425篇 |
1985年 | 505篇 |
1984年 | 570篇 |
1983年 | 526篇 |
1982年 | 707篇 |
1981年 | 614篇 |
1980年 | 545篇 |
1979年 | 370篇 |
1978年 | 353篇 |
1977年 | 354篇 |
1976年 | 299篇 |
1975年 | 277篇 |
1974年 | 283篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
The development and evaluation of a mu-capture ELISA detecting Chlamydia-specific IgM 总被引:2,自引:0,他引:2
T G Wreghitt V J Robinson E O Caul I D Paul S Gatley 《Epidemiology and infection》1988,101(2):387-395
A mu-capture enzyme-linked immunosorbent assay (ELISA) for detecting chlamydia-specific IgM was developed by use of the heat stable, lipopolysaccharide group-specific antigen and an alkaline phosphatase-labelled anti-chlamydia group-specific monoclonal antibody conjugate. The test was used to study the serological response in chlamydial respiratory tract infection among patients with acute respiratory tract symptoms in Cambridgeshire during the past 7 years. Results were compared with those of the complement fixation test (CFT) in routine use as well as those of a whole inclusion indirect immunofluorescence (WIF) test for IgM. Correlation between results of the mu-capture ELISA and those of the WIF test was 87.5%. The percentage of patients in whom specific IgM was found fell with increasing age. This may be due to lack of recall of IgM as a response to reinfection. Chlamydia-specific IgM was more likely to be detected when the CFT titre was greater than or equal to 64 and was rarely detected more than 6 months after the onset of symptoms. However, several patients less than 20 years of age were found to have specific IgM with CF antibody titres less than 64. We have found the mu-capture ELISA a useful test for the diagnosis of respiratory tract chlamydial infections, particularly in younger patients. 相似文献
72.
Gail Pairitz Jarvik Terri H. Beaty Paul R. Gallagher Paul M. Coates Jean A. Cortner 《Genetic epidemiology》1993,10(4):257-270
A sample enriched for familial combined hyperlipidemia (FCHL) was examined for evidence of an association between genotype at an apolipoprotein B (apoB) elevating locus defined by complex segregation analysis and FCHL. Complex segregation analysis detected a locus with a large effect on plasma apoB levels and was used to compute the most probable genotype of family members. None of the 35 normolipidemic adults carried a copy of the allele associated with elevated apoB levels, yet 58% of the 109 adults with FCHL carried 1 (29%) or 2 (28%) copies. Two of 28 (7%) normal children had 1 copy of this allele and none had 2 copies, while 88 of 182 (48%) children with FCHL had 1 (26%) or 2 (22%) copies. Further, 4l of 48 (85%) individuals classified as having hyperapobetalipoproteinemia did not carry a copy of this “elevated apoB” allele. Therefore, the presence of the allele associated with elevation of apoB level is highly predictive of FCHL and this association cannot be explained solely by the presence of elevated apoB levels in FCHL, suggesting that the locus controlling apoB levels may play an etiologic role in FCHL. © 1993 Wiley-Liss, Inc. 相似文献
73.
Dr. Paul O. Gubbins Pharm.D. Dr. Donna J. Occhipinti Pharm.D. Dr. Larry H. Danziger Pharm.D. 《Pharmacotherapy》1994,14(4):463-470
Study Objective . To determine the influence of treatment on the microbiologic outcome of funguria. Design . Retrospective case series. Setting . A 300-bed tertiary care teaching hospital in a large metropolitan area. Subjects . 141 hospitalized patients, 18 years of age or older, with at least one urine culture positive (≥ 102 cfu/ml) for fungi. Interventions . Retrospective review of medical records to determine the microbiologic outcome of funguria. Main Results . Funguria developed rapidly in individuals with known predisposing factors. Urinalysis did not routinely detect the presence of fungi or pyuria. Symptoms such as fever, dysuria, and frequency were generally absent. Funguria persisted whether it was due to Candida albicans or non-albicans species. There were no statistical differences in the microbiologic outcomes of treated and untreated funguria. Conclusions . Funguria is a rapidly developing, often benign and persistent process. Minimizing predisposing risks, such as removing indwelling urinary catheters, is beneficial in its management. Pharmacologic treatment of funguria due to C. albicans or non-albicans species does not influence the microbiologic outcome. 相似文献
74.
Chronic exposure to mild unpredictable stress has previously been found to depress the consumption of a palatable (1%) sucrose solution, and to attenuate food-induced place preference conditioning. In this study the effects of pramipexole (SND-919), a dopamine D2 agonist, were studied during 7–9 weeks of chronic treatment. Pramipexole (1.0 mg/kg per day) reversed the suppression of sucrose intake in stressed animals, increasing sucrose intakes above the levels seen in untreated nonstressed controls. Pramipexole also increased sucrose intake in nonstressed animals; these effects were accompanied by increases in water intake and tended to correlate with weight loss. Drug-treated stressed animals also lost weight, but in this case water intake was unaffected. A second group of animals received a higher dose of pramipexole (2.0 mg/kg per day). The effects of the two doses were very similar. After three weeks of treatment, these animals were switched to a lower dose of pramipexole (0.1 mg/kg per day). Increases in sucrose intake were maintained over three weeks of treatment at the lower dose, with significant recovery of body weight. Two further groups received the same doses of pramipexole (1.0 mg/kg for 6 weeks or 2.0 mg/kg for 3 weeks followed by 0.1 mg/kg thereafter), but received intermittent (twice-weekly) drug treatment. Intermittent pramipexole treatments also tended to increase sucrose intakes, but the results were less consistent from week to week. Following 6–8 weeks of pramipexole treatment, food-induced place preference conditioning was studied in all animals. Untreated stressed animals showed no evidence of place conditioning. Normal conditioning was seen in both groups of stressed animals treated daily with pramipexole (at 1.0 and 0.1 mg/kg) and in the group treated twice weekly at the higher dose (1.0 mg/kg); intermittent treatment at the lower dose (0.1 mg/kg) was ineffective. The results indicate that pramipexole exerts rapid anti-anhedonic effects in the chronic mild stress model. This conclusion is complicated, but not undermined, by drug-induced weight loss and by the presence of significant drug effects in nonstressed control animals. 相似文献
75.
76.
77.
Dr. Andrew G. Bostom M.D. Dr. Anne L. Hume Pharm.D. Dr. Charles B. Eaton M.D. Dr. Joseph P. Laurino Ph.D. Ms. Lisa R. Yanek B.A. Ms. Mary S. Regan B.S. Mr. William H. McQuade M.P.H. Dr. Wendy Y. Craig Ph.D. Ms. Gayle Perrone M.B.A. Dr. Paul F. Jacques Sc.D. 《Pharmacotherapy》1995,15(4):458-464
Study Objective . To determine the efficacy of high-dose ascorbate supplementation in lowering lipoprotein(a) [Lp(a)] levels in patients with premature coronary heart disease (CHD). Design . Randomized, double-blind, placebo-controlled trial. Setting . Outpatient clinic. Patients . Forty-four patients with documented premature CHD. defined as confirmed myocardial infarction and/or angiographically determined stenosis of 50% or greater in at least one major coronary artery before age 60 years. Interventions . Patients were block randomized on the basis of age, gender, and screening Lp(a) concentrations to receive ascorbate 4.5 g/day or placebo for 12 weeks. Measurements and Main Results . High-dose ascorbate was well tolerated and produced a marked elevation in mean plasma ascorbate levels (+1.2 mg/dl; p<0.001). Multiple linear regression analysis revealed no significant effect of supplementation on postintervention Lp(a) levels (p=0.39) in a model that included treatment group assignment, and baseline Lp(a) levels. Conclusions . Our findings do not support a clinically important lowering effect of high-dose ascorbate on plasma Lp(a) in patients with premature CHD. 相似文献
78.
79.
80.
Paul R. Finley R. Jane Williams Carla Fletcher 《Journal of clinical laboratory analysis》1988,2(4):249-255
We have devised assays to detect both circulating alloantibodies to platelets (indirect assay) and platelet-association IgG and IgM (direct assay) using a flow cytometric technique. A variety of patients with immune thrombocytopenia were studied. Employment of a confocal lens in the flow cytometer increased the discrimination power of the instrument. Patients with autoimmune thrombocytopenia (idiopathic thrombocytic purpura [ITP], systemic lupus erythematosus (SLE), lymphoma, leukemia, and drug-induced thrombocytopenia showed a significant increase in platelet-associated antibody. Circulating antibodies to platelets (alloantibodies) were demonstrated in cases of platelet refractoriness and neonatal isoimmune purpura. Day-today precision of the assays ranged from 3% to 6% (coefficient of variation). No interference was shown in the presence of hemoglobin (5 g/L), triglycerides (10 g/L), or polyclonal and monoclonal immunoglobulinemia (50 g/L: IgG, IgA, IgM). The sensitivity of the direct assay was 500 attograms of IgG or IgM platelet. 相似文献